BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

663 related articles for article (PubMed ID: 33689574)

  • 21. T cells of colorectal cancer patients' stimulated by neoantigenic and cryptic peptides better recognize autologous tumor cells.
    Schwarz S; Schmitz J; Löffler MW; Ghosh M; Rammensee HG; Olshvang E; Markel M; Mockel-Tenbrinck N; Dzionek A; Krake S; Arslan B; Kampe KD; Wendt A; Bauer P; Mullins CS; Schlosser A; Linnebacher M
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36460334
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor cells endowed with professional antigen-presenting cell functions prime PBLs to generate antitumor CTLs.
    Chiozzini C; Olivetta E; Sanchez M; Arenaccio C; Ferrantelli F; Leone P; Federico M
    J Mol Med (Berl); 2019 Aug; 97(8):1139-1153. PubMed ID: 31161312
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circular RNA as a source of neoantigens for cancer vaccines.
    Ren Y; Manoharan T; Liu B; Cheng CZM; En Siew B; Cheong WK; Lee KY; Tan IJ; Lieske B; Tan KK; Chia G
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38508656
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
    Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
    J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Determinants for Neoantigen Identification.
    Garcia-Garijo A; Fajardo CA; Gros A
    Front Immunol; 2019; 10():1392. PubMed ID: 31293573
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Machine learning methods and harmonized datasets improve immunogenic neoantigen prediction.
    Müller M; Huber F; Arnaud M; Kraemer AI; Altimiras ER; Michaux J; Taillandier-Coindard M; Chiffelle J; Murgues B; Gehret T; Auger A; Stevenson BJ; Coukos G; Harari A; Bassani-Sternberg M
    Immunity; 2023 Nov; 56(11):2650-2663.e6. PubMed ID: 37816353
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models.
    Zhang R; Yuan F; Shu Y; Tian Y; Zhou B; Yi L; Zhang X; Ding Z; Xu H; Yang L
    Cancer Immunol Immunother; 2020 Jan; 69(1):135-145. PubMed ID: 31807878
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Altered HLA-A2-restricted TP53 epitope induces specific CTL cytotoxicity against hepatocellular carcinoma.
    Ye C; Lin S; Hong J; Liu F; Guo G; Chen S; Zhou Z; Lin W; Li J; Ye Y
    Eur J Immunol; 2023 May; 53(5):e2250054. PubMed ID: 36794567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antigen Experienced T Cells from Peripheral Blood Recognize p53 Neoantigens.
    Malekzadeh P; Yossef R; Cafri G; Paria BC; Lowery FJ; Jafferji M; Good ML; Sachs A; Copeland AR; Kim SP; Kivitz S; Parkhurst MR; Robbins PF; Ray S; Xi L; Raffeld M; Yu Z; Restifo NP; Somerville RPT; Rosenberg SA; Deniger DC
    Clin Cancer Res; 2020 Mar; 26(6):1267-1276. PubMed ID: 31996390
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens.
    Linette GP; Becker-Hapak M; Skidmore ZL; Baroja ML; Xu C; Hundal J; Spencer DH; Fu W; Cummins C; Robnett M; Kaabinejadian S; Hildebrand WH; Magrini V; Demeter R; Krupnick AS; Griffith OL; Griffith M; Mardis ER; Carreno BM
    Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23662-23670. PubMed ID: 31685621
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression.
    Parkhurst M; Gros A; Pasetto A; Prickett T; Crystal JS; Robbins P; Rosenberg SA
    Clin Cancer Res; 2017 May; 23(10):2491-2505. PubMed ID: 27827318
    [No Abstract]   [Full Text] [Related]  

  • 32. Neoantigens as potential vaccines in hepatocellular carcinoma.
    Repáraz D; Ruiz M; Llopiz D; Silva L; Vercher E; Aparicio B; Egea J; Tamayo-Uria I; Hervás-Stubbs S; García-Balduz J; Castro C; Iñarrairaegui M; Tagliamonte M; Mauriello A; Cavalluzzo B; Buonaguro L; Rohrer C; Heim K; Tauber C; Hofmann M; Thimme R; Sangro B; Sarobe P
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35193931
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Generation of TGFβR2(-1) neoantigen-specific HLA-DR4-restricted T cell receptors for cancer therapy.
    Plewa N; Poncette L; Blankenstein T
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36822673
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.
    Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T
    Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Identification of neoantigens and development of antigen-specific immunotherapy].
    Shinohara S; Takahashi Y; Demachi-Okamura A; Matsushita H
    Rinsho Ketsueki; 2020; 61(9):1433-1439. PubMed ID: 33162546
    [TBL] [Abstract][Full Text] [Related]  

  • 36. T-cell Responses to
    Deniger DC; Pasetto A; Robbins PF; Gartner JJ; Prickett TD; Paria BC; Malekzadeh P; Jia L; Yossef R; Langhan MM; Wunderlich JR; Danforth DN; Somerville RPT; Rosenberg SA
    Clin Cancer Res; 2018 Nov; 24(22):5562-5573. PubMed ID: 29853601
    [No Abstract]   [Full Text] [Related]  

  • 37. Neoantigen: A Promising Target for the Immunotherapy of Colorectal Cancer.
    Zheng Y; Fu Y; Wang PP; Ding ZY
    Dis Markers; 2022; 2022():8270305. PubMed ID: 35211210
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Personalized neoantigen-based T cell therapy triggers cytotoxic lymphocytes expressing polyclonal TCR against metastatic ovarian cancer.
    Hung SI; Chu MT; Hou MM; Lee YS; Yang CK; Chu SY; Liu FY; Hsu HC; Pao SC; Teng YC; Chen CB; Chao A; Chung WH; Chang JW; Lai CH
    Biomed Pharmacother; 2023 Dec; 169():115928. PubMed ID: 38011788
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer.
    Matsuda T; Leisegang M; Park JH; Ren L; Kato T; Ikeda Y; Harada M; Kiyotani K; Lengyel E; Fleming GF; Nakamura Y
    Clin Cancer Res; 2018 Nov; 24(21):5357-5367. PubMed ID: 29720506
    [No Abstract]   [Full Text] [Related]  

  • 40. Identification of HLA-A2-Restricted Mutant Epitopes from Neoantigens of Esophageal Squamous Cell Carcinoma.
    Wang Z; Ran L; Chen C; Shi R; Dong Y; Li Y; Zhou X; Qi Y; Zhu P; Gao Y; Wu Y
    Vaccines (Basel); 2021 Oct; 9(10):. PubMed ID: 34696226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.